Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

Duthie MS, Guderian J, Vallur A, Bhatia A, Lima dos Santos P, Vieira de Melo E, Ribeiro de Jesus A, Todt M, Mondal D, Almeida R, Reed SG.

Eur J Clin Microbiol Infect Dis. 2014 Apr;33(4):639-49. doi: 10.1007/s10096-013-1999-1. Epub 2013 Oct 31.

2.

Interleukin 6 during active visceral leishmaniasis and after treatment.

van der Poll T, Zijlstra EE, Mevissen M.

Clin Immunol Immunopathol. 1995 Oct;77(1):111-4.

PMID:
7554475
3.

Leishmaniasis in Sudan. Visceral leishmaniasis.

Zijlstra EE, el-Hassan AM.

Trans R Soc Trop Med Hyg. 2001 Apr;95 Suppl 1:S27-58.

PMID:
11370250
4.

Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh.

Islam S, Kenah E, Bhuiyan MA, Rahman KM, Goodhew B, Ghalib CM, Zahid MM, Ozaki M, Rahman MW, Haque R, Luby SP, Maguire JH, Martin D, Bern C.

Am J Trop Med Hyg. 2013 Aug;89(2):345-53. doi: 10.4269/ajtmh.12-0711. Epub 2013 Jul 1.

5.

Pre- & post-treatment evaluation of immunological features in Indian visceral leishmaniasis (VL) patients with HIV co-infection.

Sinha PK, Bimal S, Singh SK, Pandey K, Gangopadhyay DN, Bhattacharya SK.

Indian J Med Res. 2006 Mar;123(3):197-202.

PMID:
16778304
6.

Serum cytokines associated with severity and complications of kala-azar.

Costa DL, Rocha RL, Carvalho RM, Lima-Neto AS, Harhay MO, Costa CH, Barral-Neto M, Barral AP.

Pathog Glob Health. 2013 Mar;107(2):78-87. doi: 10.1179/2047773213Y.0000000078.

7.

Serum cytokine profile in the subclinical form of visceral leishmaniasis.

Gama ME, Costa JM, Pereira JC, Gomes CM, Corbett CE.

Braz J Med Biol Res. 2004 Jan;37(1):129-36. Epub 2003 Dec 18.

8.

Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.

Burza S, Sinha PK, Mahajan R, Sanz MG, Lima MA, Mitra G, Verma N, Das P.

PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2611. doi: 10.1371/journal.pntd.0002611. eCollection 2014.

9.

Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India.

Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, Verma N, Balasegaram M, Das P.

PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2603. doi: 10.1371/journal.pntd.0002603. eCollection 2014. Erratum in: PLoS Negl Trop Dis. 2014 Apr;8(4):e2813. Balasegarem, Manica [corrected to Balasegaram, Manica].

10.

IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.

Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, Rahman M, Kar S, Goswami R, Guha SK, Pramanik N, Saha B, Ali N.

J Immunol. 2007 Oct 15;179(8):5592-603.

11.

Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.

Singh RP, Picado A, Alam S, Hasker E, Singh SP, Ostyn B, Chappuis F, Sundar S, Boelaert M.

Trop Med Int Health. 2012 Nov;17(11):1345-8. doi: 10.1111/j.1365-3156.2012.03067.x. Epub 2012 Aug 12.

12.

Cytokines and visceral leishmaniasis: a comparison of plasma cytokine profiles between the clinical forms of visceral leishmaniasis.

Costa AS, Costa GC, Aquino DM, Mendonça VR, Barral A, Barral-Netto M, Caldas Ade J.

Mem Inst Oswaldo Cruz. 2012 Sep;107(6):735-9.

13.

Cytokine profiles amongst Sudanese patients with visceral leishmaniasis and malaria co-infections.

van den Bogaart E, Talha AB, Straetemans M, Mens PF, Adams ER, Grobusch MP, Nour BY, Schallig HD.

BMC Immunol. 2014 May 1;15:16. doi: 10.1186/1471-2172-15-16.

14.

Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India.

Patra P, Guha SK, Maji AK, Saha P, Ganguly S, Chakraborty A, Kundu PK, Sarker S, Ray K.

Indian J Pharmacol. 2012 Jul-Aug;44(4):500-3. doi: 10.4103/0253-7613.99326.

15.

Low serum zinc levels in an endemic area of visceral leishmaniasis in Bihar, India.

Mishra J, Carpenter S, Singh S.

Indian J Med Res. 2010 Jun;131:793-8.

16.

Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar.

Ansari NA, Saluja S, Salotra P.

Clin Immunol. 2006 Jun;119(3):339-45. Epub 2006 Mar 15.

PMID:
16540374
17.

Serum chemokine profiles in visceral leishmaniasis, HIV and HIV/ visceral leishmaniasis co-infected Ethiopian patients.

Sisay Z, Berhe N, Petros B, Tegbaru B, Messele T, Hailu A, Wolday D.

Ethiop Med J. 2011 Jul;49(3):179-86.

PMID:
21991751
18.

Soluble receptors for tumor necrosis factor as markers of disease activity in visceral leishmaniasis.

Zijlstra EE, van der Poll T, Mevissen M.

J Infect Dis. 1995 Feb;171(2):498-501.

PMID:
7844400
19.
20.

Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?

Salih NA, van Griensven J, Chappuis F, Antierens A, Mumina A, Hammam O, Boulle P, Alirol E, Alnour M, Elhag MS, Manzi M, Kizito W, Zachariah R.

Trop Med Int Health. 2014 Feb;19(2):146-52. doi: 10.1111/tmi.12238. Epub 2014 Jan 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk